paclitaxel,olaparib,bevacizumab,carboplatin,durvalumab
roche,merck,astrazeneca
['brca', 'duo-o', 'ovarian']
a statistically significant and clinically meaningful improvement in pfs was observed in patients with newly diagnosed ovarian cancer without a brca1/2 mutation, according to findings from the phase 3 duo-o trial presented at #asco2023. 
Oncology news and insights from leading researchers and cancer centers.